Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry

Secondary acute myeloid leukemia (s-AML) patients have a poor prognosis and currently the only curative therapy is allogeneic stem-cell transplant (HSCT). However, we do not yet know whether transplantation is sufficient to reverse the poor prognosis compared to de novo AML patients. We analyzed sur...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematological oncology 2023-10, Vol.41 (4), p.753-761
Hauptverfasser:	Núñez-Torrón Stock, Claudia, Jiménez Chillón, Carlos, Martín Moro, Fernando, Marquet Palomanes, Juan, Velázquez Kennedy, Kyra, Piris Villaespesa, Miguel, Roldán Santiago, Ernesto, Rodríguez Martín, Eulalia, Chinea Rodríguez, Anabelle, García Gutiérrez, Valentín, Moreno Jiménez, Gemma, López Jiménez, Javier, Herrera Puente, Pilar
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Allografts Conditioning Flow cytometry Leukemia Medical prognosis Minimal residual disease Ontogeny Prognosis Remission Stem cell transplantation Survival Transplantation Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Secondary acute myeloid leukemia (s-AML) patients have a poor prognosis and currently the only curative therapy is allogeneic stem-cell transplant (HSCT). However, we do not yet know whether transplantation is sufficient to reverse the poor prognosis compared to de novo AML patients. We analyzed survival after HSCT comparing a cohort of 58 patients with s-AML versus 52 de novo patients who were transplanted between 2012 and 2020. Patients with s-AML had worse event-free survival (EFS) (p = 0.001) and overall survival (OS) (p
ISSN:	0278-0232 1099-1069
DOI:	10.1002/hon.3160